Technology
Health
Pharmaceutical
Nightstar Therapeutics
$25.299876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$25.29
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.02 (-0.08%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell NITE and other stocks, options, ETFs, and crypto commission-free!
About
Nightstar Therapeutics plc American Depositary Shares, also called Nightstar Therapeutics, is a clinical-stage gene therapy holding company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. Read More The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.
Employees
27
Headquarters
London, Greater London
Founded
2017
Market Cap
730.88M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
176.30K
High Today
$25.44
Low Today
$25.25
Open Price
$25.25
Volume
246.70K
52 Week High
$29.55
52 Week Low
$9.59
Collections
Technology
Health
Pharmaceutical
Therapy
Medical
2017 IPO
UK
Europe
News
Seeking AlphaMar 12
Biogen Is Next In Line With Purchase Of Gene Therapy Biotech
There has been a massive increase this year for either acquisitions or partnerships being formed with gene therapy companies, with the likelihood that more deals are likely on the way.
Price Paid on Robinhood
61% Higher
Right Now
52 Week Low
$9.59
Average Price Paid
$15.71
52 Week High
$29.55
Earnings
-$0.52
-$0.40
-$0.27
-$0.15
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
—
Actual
—